|
|
Volumn 13 Suppl 4, Issue , 2008, Pages 10-15
|
|
Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with tremelimumab (CP-675,206).
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CP-675,206;
CYTOTOXIC T LYMPHOCYTE ANTIGEN 4;
CYTOTOXIC T-LYMPHOCYTE ANTIGEN 4;
LEUKOCYTE ANTIGEN;
MONOCLONAL ANTIBODY;
TICILIMUMAB;
UNCLASSIFIED DRUG;
HUMAN;
IMMUNOLOGY;
IMMUNOTHERAPY;
MELANOMA;
PHASE 1 CLINICAL TRIAL;
PHASE 2 CLINICAL TRIAL;
REVIEW;
ANTIBODIES, MONOCLONAL;
ANTIGENS, CD;
CLINICAL TRIALS, PHASE I AS TOPIC;
CLINICAL TRIALS, PHASE II AS TOPIC;
HUMANS;
IMMUNOTHERAPY;
MELANOMA;
MLCS;
MLOWN;
|
|
EID: 58749114723
PISSN: None
EISSN: 1549490X
Source Type: Journal
DOI: 10.1634/theoncologist.13-S4-10 Document Type: Review |
|
Times cited : (52)
|
|
References (10)
|
